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Abstract
A 6 year old female with symptoms of small bowel obstruction underwent an exploratory laparotomy which
revealed widespread evidence of inflammatory fibrotic adhesions involving the jejunal mesentery. In view of persis-
tent growth failure, chronic anaemia, elevated acute phase reactants and imaging evidence of a diffuse progressive
inflammatory process, the child was treated with corticosteroids and methotrexate with complete response. The lit-
erature on juvenile idiopathic sclerosing mesenteritis has been reviewed.
Background
Idiopathic sclerosing mesenteritis (ISM) is an uncom-
mon disease involving the small bowel mesentery and
characterised by chronic inflammatory changes ulti-
mately progressing to fibrosis. The first reported series
featured 34 cases of “retractile mesenteritis and mesen-
teric sclerosis"; published in 1924 [1-3]. It has been
described variously as fibrosing mesenteritis, retractile
mesenteritis, liposclerotic mesenteritis, xanthogranulo-
matous mesenteritis, mesenteric Weber Christian dis-
ease and systemic nodular panniculitis [4]. These names
possibly reflect the underlying pathology involved with
mesenteric lipodystrophy (predominant fatty degenera-
tion), mesenteric panniculitis (chronic inflammation)
and retractile mesenteritis (predominant fibrosis) being
the common histologic variants. It has been postulated
that these variants represent the varied spectrum of a
single disease process which could be termed idiopathic
sclerosing mesenteritis [5].
Though the exact aetiology remains obscure, proposed
mechanisms include prior abdominal trauma/surgery,
autoimmunity, infection and ischemia [6]. A wide range
of therapeutic initiatives have been reported including
corticosteroids, colchicine, immunosuppressives (cyclo-
phosphamide and azathioprine), tamoxifen, thalidomide
and hormonal therapies with varying success [6,7]. The
disease is considered rare in the pediatric age group
with only 16 cases reported to date. We describe a case
of ISM in a young girl who was treated successfully with
corticosteroids and methotrexate, and briefly review the
pediatric literature on this subject.
Case presentation
A 6 year old girl presented at a local hospital with an
acute onset of abdominal pain, nausea and bilious
vomiting. A history of constipation, recurrent vomiting
associated with high fever in the preceding 12 months
was elicited. Clinical examination was reported to be
normal at the time. Complete blood counts revealed
haemoglobin (Hb) 94 g/l, WBC 18.4 × 0
9/l (Absolute
PMN 15.6 × 10
9/l, Lymph 2.0 × 10
9 /l) and platelets 663
×1 0
9 /l. Her ESR was elevated at 54 mm/hr [1-15 mm/
hr) and CRP 84 mg/l (<10 mg/l). Ultrasonography of
the abdomen revealed diffuse, mesenteric lymphadeno-
pathy. A barium meal with follow through suggested a
small bowel obstruction. A laparotomy showed extensive
intraperitoneal adhesions, mesenteric lymphadenopathy
and a tight jejunal band with obstruction. The adhesions
were divided, the obstruction was relieved and the
patient’s bowel function recovered steadily. Tissue cul-
tures were negative. Histopathological analysis of the
peritoneal tissue revealed fibro-fatty tissue with exten-
sive fibrosis throughout, infiltrated by many scattered
lymphocytes, plasma cells and occasional neutrophils
but no malignant cells. The single lymph node examined
revealed dilated sub-capsular sinuses with an expanded
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immunoblast with no granulomas, Reed Sternberg cells
or any evidence of lymphoma. Ziehl-Neelsen stains were
negative for tuberculosis organisms as was subsequent
culture. The clinical condition improved slowly over the
subsequent 2 weeks and she was discharged on oral iron
supplements. No evidence of mono-clonality was seen
on flow cytometry for immuno-phenotyping of lymph
node tissue.
Three months later, she moved interstate and pre-
sented to the gastroenterology clinic at our hospital with
continued weight loss and an exacerbation of abdominal
pain and vomiting of fecal matter. Upper and lower
endoscopies were normal. MRI of the abdomen revealed
apparent thickening of a loop of proximal jejunum in
the left mid abdomen with enlarged mesenteric lymph
nodes. CT scan revealed evidence of a subtle attenuation
in the mesentery with diffuse lymphadenopathy (Figure
1A). The symptoms of obstruction settled with conser-
vative management. At one month follow up, her hae-
moglobin remained depressed, 87 g/l, WBC 15.0 × 10
9/l
with thrombocytosis. She had lost 7 kgs in weight (from
the first presentation), had recurrent abdominal pain
and required a second admission for a partial obstruc-
tion which resolved with conservative management.
A rheumatology consultation was made. Review of the
case revealed multiple episodes of subacute small bowel
obstruction with chronic anaemia, weight loss, and a
chronic inflammatory process with fibrosis on mesen-
teric biopsy and elevated acute phase reactants. Further
investigations revealed a borderline positive ANA of
1:40 (speckled pattern), a negative dSDNA and rheuma-
toid factor (RF). Total serum proteins were 82 g/l, albu-
min 40 g/l (32-48 g/l), globulins 42 g/l (23-35 g/l), and
serum IgG 15.7 g/l (6-12.3 g/L) indicating mild
hypergammaglobulinemia. IgG subclasses IgG1 11.1(4.0-
10.8 g/L), IgG2 4.3 (0.8-4.1 g/L), IgG 30.4 (0.1-1.4 g/L),
IgG4 1.47 (<1.9 g/L) were unremarkable. An abdominal
angiogram was done to screen for major vessel vasculitis
such as polyarteritis nodosa, and was negative.
A diagnosis of idiopathic sclerosing mesenteritis was
made and the child was treated with 3 daily pulses of
methyl prednisolone therapy repeated monthly for 3
months. She made a remarkable and rapid clinical
recovery with marked reduction in fatigue, abdominal
pain and resolution of fever within 2 weeks. Four weeks
into treatment, laboratory investigations revealed signifi-
cant improvement; Hb 118 g/l, WBC 10.1 × 10
9/l plate-
lets 490 × 10
9/l and ESR 3 mm/hr. Subcutaneous
methotrexate (10 mg/m
2 ), total dose 10 mg once a
week was started for long term immunomodulation and
steroid sparing effects. At 6 months follow - up from
the onset of treatment, she had gained 3 kgs, was com-
pletely asymptomatic and her laboratory investigations
remained normal. Her repeat CT scan this time had
revealed resolution of the lymphadenopathy with normal
mesentery (Figure 1b). Currently at 18 months follow
up, she is under regular 3 monthly follow-up, off ster-
oids and only on subcutaneous methotrexate at (10 mg/
m
2) now 12.5 mg. Figure 2 illustrates the impressive and
sustained response to treatment evidenced by her hae-
moglobin and ESR results over time.
Discussion
First reported in 1924 as ‘retractile sclerosing mesenteri-
tis’, ISM was reprised in a case series which reported it
to be a benign disease in general. ISM is considered a
rare disorder of late adult life with relatively few cases
reported in world literature [1-3]. Only 3 major case
series have been reported in adults comprising 53, 84
Figure 1 A (Pre treatment) Radiological findings demonstrating altered attenuation of mesentery and diffuse lymphadenopathy
(white arrows). B (Post treatment) Resolution of lymphadenopathy.
Viswanathan and Murray Pediatric Rheumatology 2010, 8:5
http://www.ped-rheum.com/content/8/1/5
Page 2 of 8Haemoglobin response to treatment
0
20
40
60
80
100
120
140
-5 0 5 10 15 20
Months of treatment
H
b
ESR response to treatment
0
10
20
30
40
50
60
70
80
90
100
-5 0 5 10 15 20
Months of treatment
E
S
R
Figure 2 Response to treatment of patients ESR and Haemoglobin in month since the start of treatment.
Viswanathan and Murray Pediatric Rheumatology 2010, 8:5
http://www.ped-rheum.com/content/8/1/5
Page 3 of 8and 92 patients [5,6,8]. To our knowledge, only 17
pediatric cases including our own have been reported
(see Table 1), with no gender predominance and age at
diagnosis averaging 6.5 years (range 18 months -12
years).
Various patho-physiological mechanisms suggested
include previous surgery, trauma, hypoxia, allergy, infec-
tion and autoimmunity [6,9,10]. Concurrent intra
abdominal pathologies have been reported in adults
including lymphoma and ovarian tumours. One child
had a coincidental presence of a Meckels diverticulum
[11] while another had a blunt trauma to the abdomen
a week before developing clinical manifestations. (See
table 1). Other associated immuno-hematological
anomalies such as common variable immunodeficiency,
polyclonal gammopathies, acute myeloid leukaemia and
myelodysplasias have been reported in adults.
Understandably monoclonal/oligoclonal B cell expansion
has been suggested as a possible mechanism, as it has in
a possibly related disorder, retroperitoneal fibrosis.
Inflammation in ISM has been attributed to adipocyto-
kines, including adiponectin, resistin, leptin, IL-6, and
TNF-a. Macrophages found in adipose tissue may trans-
differentiate from local preadipocytes, supporting the
hypothesis that adipocytes and macrophages may be
interconvertible, implicating mesenteric adipose tissue in
disorders such as ISM [12]. Autoimmunity has been
associated with ISM, including the co-occurrence of
Sjogren syndrome, sarcoidosis, rheumatoid arthritis and
ankylosing spondylitis. Similarly an association of ISM
and other sclero-fibrosing disorders in other organs has
been reported in adults [13,14]. (More recently, ISM has
been regarded as a possible subset of IgG4 related scler-
osing disorders with increased expression in the lesional
Table 1 Clinical manifestations and course of illness in 17 children with sclerosing mesenteritis
Pt.
no
Author/year Age/
Sex
Presenting features/
duration
Treatment Outcome Special features (if
any)
1 McGee et.al
[18](1965)
6/M A, Asc/unknown
duration
Sx Died ,3 weeks post surgery
(Bacterial endocarditis )
No ‘persistent fibrosis
on autopsy.’
2 Soergel[16]et.
al (1966)
14/M A, WL, F/Recurrent
symptoms over 12 yrs
Sx Died ,12 yrs after initial
symptom
Steatorrhea, secondary
amyloidosis
3 Black et.al
[19](1968)
8/F A, N, V, D, F, M/6 weeks Sx, Partial resection and
ileocolostomy
UR/NF ,5 mths Blunt trauma one week
prior.
4 Spark et.al[17]
(1971)
6/M A/M Two weeks Sx/Hemi colectomy with ileo colic
anastomosis
UR/NF ,9 mths ————————
5 Misaka et.al
[20](1977)
4/F A/C/V/Asc Sx/enterostomy with resection UR/NF ,12 mths —————————
6 Melo et.al
[21](1980)
13/F A, N, V, M Sx/hemicolectomy NR ————————
7 Dor et.al
(1982)
10/F F Sx/enterectomy, partial splenectomy
and partial pancreatectomy
NR SLE
8 Cakmak
22et.
al (1986)
4/M A/C/F/V, acute onset Sx/Transverse laparotomy UR/NF, 20 mths. Recurrence after 2
weeks.
9 Jona et.al
[23](1987)
5/F A, F/7 days Sx/Right hemicolectomy UR/NF ,51/2 yrs Bacterial peritonitis.
10 Davis et.al
24
(1992)
3/M A, An, V/one day Sx/No resection. UR/NF 2 mths. Hemo Peritoneum
11 Ueda et.al
[25](1997)
12/F V, M/2 days SRAM UR/NF ,6 months Fulminant hep A with
recurrent ascites
12 Ito [20]et.al
(1998)
8/M NR SRAM UR/NF, 9 years
13 Hakguder et.
al
11(2000)
4/M A, N, An/Not specified SRAM UR/NF, 6 months. Meckels diverticulum
14 Kawano [20]
et.al (2003)
2/M F/1 month SRAM UR/NF ———————
15 Kawano [20]
et.al (2003)
4/M F, M/Not specified, SRAM UR/NF —————————
16 Kawano [20]
et.al (2003)
6/F F, M/Not specified SRAM UR/NF ————————
17 Our case
(2008)
6/F A, V, WL, C/Recurrent
episodes 6 months
Sx, Steroids, Methotrexate UR/NF, 6 months. Methotrexate first
reported pediatric case.
Pt; Patient, A; Abdominal pain, An; Anorexia, Asc; Ascites, W; Weight loss, F; Fevers, M; Mass N/V; Nausea/Vomiting, C; Constipation, D; Diarrhoeas, Mtx;
Methotrexate, St; Steroids, Sx; Surgery, SRAM; Surgical resection and anastomosis, UR; Uneventful recovery, NF; Normal follow up, NR; Not reported.
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this case but the biopsy was not specifically stained for
subclasses [15]. Apart from one child with SLE none of
these has been reported in pediatric literature to date
[16]. Our case did exhibit some features of autoimmu-
nity with a positive ANA and hypergammaglobulinemia.
The onset of the disease may be acute, insidious or
have recurring episodes before the actual diagnosis is
made [17]. Varied clinical manifestations have been
reported, primarily due to mechanical effects of the
encasing mass/inflammation involving bowel loops,
mesenteric vessels and lymphatics. These include
abdominal pain with a clinically palpable mass, bilious
vomiting, diarrhoea, constipation and abdominal disten-
sion. Associated features of chronic inflammation
including prolonged pyrexia, weight loss, and progres-
sive anaemia can be seen but may be more prominent
in the early phase.
In the pediatric cases, of the 17 children, 4 were
described as mesenteric panniculitis while the remaining
13 termed sclerosing mesenteritis. Eleven (64.7%) chil-
dren presented with abdominal pain, 7 (41%) had vomit-
ing, 4 (23.5%) with bowel symptoms in the form of
constipation or diarrhoea, 8 (47%) with associated fever
and 2 (11.7%) with weight loss. Only 5 (29%) children
had a clinically palpable mass corroborated on explora-
tion. Laboratory investigations were usually non specific
ranging from normal to neutrophilic leucocytosis and
variable elevation of acute phase reactants. Five of the
13 (38%) children tested demonstrated anemia and 9
(62%) leucocytosis. 4 (30%) children had normal white
cell counts. Elevated acute phase reactants ESR/CRP
were only reported in 5 children [18-26].
Most cases are diagnosed on surgical intervention, but
advances in imaging techniques have helped identify fea-
tures that may suggest a diagnosis of ISM. The various
imaging patterns reported in children has been sum-
marised in Table 2. Such imaging may provide valuable
clues to diagnosis, clinical response and progression.
Plain roentgenograms are usually non specific. However
small-bowel series often show separation of loops with
kinking and angulation of the small bowel, suggesting a
serosal process. Folds may be thickened because of
either extension of the mesenteric process into the sub-
mucosa or edema from lymphatic obstruction. The
colon may occasionally be involved, with narrowing and
rigidity; thumb printing also has been reported [27,28].
Ultrasonography may help delineate normal from
inflammatory mesenteric fat, the latter demonstrating a
homogenous echogenicity [29]. It has been reported in
only 3 of the pediatric cases revealing a homogeneous
low echoic mass in the involved areas. The CT appear-
ance of sclerosing mesenteritis may vary from subtle
increased attenuation in the mesentery to a solid soft-
t i s s u em a s s .T h e r em a yb ep r e s e r v a t i o no ff a ta r o u n d
the mesenteric vessels, a phenomenon that is referred to
as the “fat ring sign”, a finding that may help distinguish
sclerosing mesenteritis from other mesenteric processes
such as lymphomas [30]. In addition, Sabate et al
described the presence of a tumoral pseudocapsule in
50% of patients with mesenteric panniculitis [31]. Our
case showed features of severe diffuse mesenteric adeno-
pathy on CT. MRI usually reveals a low signal suggest-
ing a mature fibrotic reaction. T2-weighted or fat-
suppressed pulse sequences may help distinguish benign
end stage fibrofatty proliferation from malignant
tumours such as lymphoma [32]. Assessment of large to
medium-sized vessels depicting the flow patterns and
the presence of collaterals is also possible with MR ima-
ging. MRI findings are reported in only 2 children with
evidence of low signal intensities suggesting fibrosis in
one case [21]. In our case, a young child, movement
artefact degraded images on MR making interpretation
difficult.
Most histopathological analyses show varied degree of
fibrosis, chronic inflammation, and fat necrosis with the
infiltrate being predominantly lymphocytes and eosino-
phils with no evidence of vasculitis or vascular thicken-
ing. Foci of dystrophic calcification have been
occasionally reported [5]. The findings at biopsy in the
pediatric series were consistent with macroscopic
changes ranging from increased adipose tissue to wide-
spread panniculitis and extensive fibrosis (Table 3).
No specific guidelines regarding the management of
ISM exist and various medical and surgical modalities
that have been tried. Use of anti-inflammatory, anti
fibrotic and immunomodulatory agents such as cortico-
steroids, methotrexate, azathioprine, colchicine, thalido-
mide and Tamoxifen have all been reported either alone
or in combination with varied degrees of success [6,7].
Thalidomide might act by modulating the production of
tumor necrosis factor-alpha (TNF-a) and other cyto-
kines along with its inhibitory effects on angiogenesis
[33]. Though reported in adults [34], our case is to our
knowledge the first child to be treated with methotrex-
ate. We used methotrexate because of the evidence of
ongoing chronic inflammation and in part the reported
role of methotrexate in ameliorating adiponectin which
may thus inhibit the migration of macrophages to the
mesenteric adipose tissue and suppress local TNF-a dri-
ven proinflammatory pathways [35].
Surgical exploration for diagnostic and therapeutic
(adhesiolysis, debulking with or without resection anasto-
mosis) purposes has been reported with all the children
having some form of surgical intervention with only two
cases not having actual tissue resection. Resection or
debulking probably has a role in alleviating symptoms but
may not help in prevention of disease progression.
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Pt no Barium studies CT
1 Displaced DC, Small bowel obstruction, splenomegaly NR
2 Initial normal, then thickened folds, segmentation of contrast
material.
NR
3 Normal NR
4 Mass displacing cecum &AC. NR
5 ————— NR
6 Mass & narrowing AC. NR
7 NR Heterogeneous, solid TM between spleen, left kidney and pancreas
8N R N R
9 Mass on medial AC NR
10 Normal NR
11 Narrowing of SC Soft Tm in mid abdomen around AC to DC. Retraction of TC, Dilated
AC
12 NR NR
13 NR NR
14 NR Solid soft TM over the lower TC
15 NR E/o TM over the hepatic flexure
16 Tumor mass displacing the Splenic flexure NR
17 NR Mesenteric adenopathy
DC; Descending colon, NR; Not reported, AC; Ascending colon, TM; Tissue mass SC; sigmoid colon, TC; Transverse colon.
Table 3 Anatomic Involvement and pathological findings on biopsy.
Pt. no Anatomic area of involvement Pathology
1 Mesentery (AC and TC) FB with LI
2 Mesentery (SB, largely at root) Fat necrosis(early phase )®Extensive FB (later )
3 Mesentery (TI), plaques on UT, OV, PP. FB with absent residual fat
4 T M in mesentery (TI, IC and Ap ) FB with LI and PI.
5 Mesentery (I, AC, TC, UT) FB with LI and PI.
6 Mesentery (AC). FB with EI.
7 TM (MG adherent to the Splenic artery) Panniculitis and severe fibrinoid necrosis.
8 Mesentery (GC and TC ) Severe inflammatory changes minimal FB.
9 TM ( right colon and H (No obstruction )) FB
10 Hemoperitoneum, TM (SI and TC ) FB with LI and foamy macrophages.
11 TM (Whole colon and MC (except RS) with perforation, normal SI. FB with necrosis and LI.
12 Mesentery (IC) Increased adipose tissue with FB with necrosis and
LI.
13 TM FB with inflammatory infiltration.
14 Mesentery (TC ) FB with inflammatory infiltration
15 Greater omentum (TC) FB with LI and PI.
16 Mesentery (S) FB with LI and F.
17 Extensive intraperitoneal adhesions, jejunal band with evidence of proximal
obstruction
Fibro fatty changes with extensive LI and PL
AC; Ascending colon , TC; Transverse colon , FB; Fibrosis , LI; Lymphocytes infiltration , SB; Small bowel , I/TI; Ileum/Terminal Ileum, Ut; Uterus, Ov; Oviducts, TM;
Tumour mass, PP; Parietal peritoneum, MG; Mesogastrium, BL; Broad ligaments, RS; Rectosigmoid colon, TM; Transverse mesocolon, S; Splenic flexure,I C ;
Ileocecum, GC; Gastrocolic omentum, H; Hepatic flexure EI; Eosinophils infiltration, PL; Plasma cells, F; Fibroblasts
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Widely believed to have a good outcome in adults, the
paucity of reported pediatric cases and long term follow
up makes it difficult to plan management and prognosti-
cate in children.
Decisions regarding the most appropriate form and
duration of therapy in children should probably be guided
by the severity and chronicity of symptomatology, growth
of the child, and inflammatory markers. It seems rational
that unless there is severe obstruction, medical/non-surgi-
cal management might be considered. Serial imaging is
probably not indicated unless warranted by a clinical dete-
rioration. Studies in adults have reported median duration
of medical treatment between 2-30 months with recur-
rences up to 2 years after discontinuation though long
term outcomes are not well reported [6]). Acute manage-
ment of the condition with corticosteroids and introduc-
tion of a steroid sparing agent such as methotrexate if
treatment seems likely be required for 3 months or more
could be considered a reasonable. We suggest that treat-
ment might be continued from at least 6 months from the
time clinical and laboratory remission, as for other similar
chronic inflammatory conditions of childhood.
Mortality secondary to ISM has been reported in 2
children and 4 adults [16,18,33]). Chronic inflammatory
diseases have a much higher morbidity in growing chil-
dren and a close follow up and individualisation of care
is warranted with such a potentially variable course and
outcome.
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